New drug helps with Parkinson’s movement problems

	Tweet

An experimental drug called safinamide improves movement in patients with early Parkinson’s disease, researchers report.

“Safinamide is a novel (nerve-protecting drug) combining several properties of potential benefit in Parkinson’s disease,” Dr. R. G. Fariello, of Newron Pharmaceuticals, Milan, Italy, and colleagues write in the medical journal Neurology. 

In their study, the team examined whether safinamide improves symptoms in patients with moderately severe Parkinson’s disease. The study included 172 patients who were randomly selected to receive high-dose safinamide, low-dose safinamide, or an inactive “placebo” for 12 weeks.

Participants were considered treatment responders if they experienced a 30 percent or greater improvement on a standard test of Parkinson’s symptoms.

In the high- and low-dose safinamide groups, 38 and 31 percent of subjects were treatment responders, respectively. In contrast, the percentage of treatment responders in the placebo group was 21 percent.

In a related analysis, the authors found that safinamide seemed to magnify the benefits of a different anti-Parkinson’s drug.

SOURCE: Neurology, August 24, 2004. 

RELATED STORIES:
Sleeping disorder linked to risk of stroke death   Deep Brain Stimulation Found to be Effective in Children with Generalized Primary Dystonia   Advances in stroke detection and treatment   Alzheimer’s disease may be easily misdiagnosed   Blocking Protein May Help Ease Painful Nerve Condition   Mouse gene suppresses Alzheimer’s plaques and tangles   Gene Mutation May Influence Age at Onset of Parkinson’s Disease   New Web tool may help predict risk of second stroke   New Test Shows Promise For Accurate Early Diagnosis Of Turner Syndrome   Worms take the sniff test to reveal sex differences in brain   MS drug prevented fatal heart condition in lab study   Immune system gene linked with Parkinson’s: study

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]